Published in Women's Health Weekly, April 3rd, 2008
"BioSante has had an exciting year and that excitement continues," said Stephen M. Simes, BioSante's president and chief executive officer. "We have made significant advances with the products in our pipeline, in particular with regard to LibiGel(R), our transdermal testosterone gel for the treatment of female sexual dysfunction (FSD). We reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) that sets in motion a process by which we are pursuing aggressively the Phase III clinical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly